Welcome to the e-CCO Library Archive!
Rutgeerts score and endoscopy based management of postoperative Crohn's disease are useful in patients already receiving pharmacological treatment for recurrence prevention
I. Blazquez1, Y. Gonzalez-Lama1, C. Suarez1, V. Matallana1, M. Calvo1, V.M. Isabel1, L. Abreu1, 1Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology, Majadahonda, Spain
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort study (CREOLE)
Y. Bouhnik*1, F. Carbonnel2, D. Laharie3, C. Stefanescu1, X. Hébuterne4, V. Abitbol5, M. Nachury6, H. Brixi7, A. Bourreille8, L. Picon9, A. Bourrier10, M. Allez11, L. Peyrin-Biroullet12, J. Moreau13, G. Savoye14, M. Fumery15, S. Nancey16, X. Roblin17, R. Altwegg18, G. Bouguen19, G. Bommelaer20, S. Danese21, E. Louis22, J.-Y. Mary23
1Hôpital Beaujon, Gastroentérologie, MICI et Assistance Nutritive, Clichy, France, 2Hôpital Bicêtre, Service d'Hépato-Gastro-Entérologie, Le Kremelin Bicêtre, France, 3Hôpital Haut-Lévêque, Service d' hépato-gastroentérologie et d' oncologie digestive, Pessac, France, 4Hopital de l'Archet 2, Service de Gastro-Entérologie & Nutrition Clinique, Nice, France, 5Hôpital Cochin, Service de Gastro Enterologie, Paris, France, 6Hôpital Claude Huriez, Service des Maladies de l'appareil digestif et nutrition, Lille, France, 7Hôpital Robert Debré, Service de Gastro Enterologie, Reims, France, 8Hôpital Hôtel Dieu, Service d'Hépato-gastro-entérologie et cancérologie digestive, Nantes, France, 9Hôpital Trousseau, Service d'Hépato-Gastro-Onco-Entérologie, Tours, France, 10Hôpital Saint-Antoine, Service de Gastroentérologie & Nutrition, Paris, France, 11Hôpital Saint-Louis, Service Hépato-gastroentérologie, Paris, France, 12Hôpital de Brabois, Service Hépato Gastro-Entérologie, Nancy, France, 13Hôpital Rangueil, Service Gastro-entérologie et Nutrition, Toulouse, France, 14Hôpital Charles Nicolle, Service d'hépato-gastro-entérologie et de nutrition, Rouen, France, 15Hôpital Nord, Service d'Hépato-Gastroentérologie, Amiens, France, 16Centre Hospitalier Lyon-Sud, Service d'Hépato-gastro-entérologie, Lyon, France, 17Service Gastro-entérologie et Hépatologie, CHU Saint-Etienne, Saint-Etienne, France, 18Hôpital Saint Eloi, Service d'Hépato-gastro-entérologie, Montpellier, France, 19Hôpital Pontchaillou, Service des maladies de l'appareil digestif, Rennes, France, 20CHU Estain, Service d'Hépatologie Gastro-Enterologie, Clermont Ferrand, France, 21Humanitas Research Hospital, Department of Gastroenterology, Milan, Italy, 22CHU Sart Tilman, 20Service de Gastro-entérologie, hépatologie et oncologie digestive, Liege, Belgium, 23Hôpital Saint-Louis, DBIM, Paris, France
Early assessment of thiopurine metabolites predicts the occurrence of leukopenia in inflammatory bowel disease patients
D. Wong1, M. Coenen2, L. Derijks3, C. van Marrewijk2, S. Vermeulen2,4, A. Verbeek4, B. Franke2,5, H.-J. Guchelaar6, D. De Jong7, L. Engels8, P. Hooymans1, 1Orbis Medical Centre, Clinical pharmacy & Toxicology, Sittard-Geleen, Netherlands, 2Radboud University Medical Centre, Human Genetics, Nijmegen, Netherlands, 3Máxima Medical Centre, Clinical Pharmacy, Veldhoven, Netherlands, 4Radboud University Medical Centre, Health Evidence, Nijmegen, Netherlands, 5Radboud University Medical Centre, Psychiatry, Nijmegen, Netherlands, 6University Medical Centre, Clinical Pharmacy and Toxicology, Leiden, Netherlands, 7Radboud University Medical Centre, Gastroenterology, Nijmegen, Netherlands, 8Orbis Medical Centre, Gastroenterology and Hepatology, Sittard-Geleen, Netherlands
Anti-TNF withdrawal in IBD: Relapse and recapture rates and predictive factors from 160 patients in a pan-UK study
N.A. Kennedy*1, B. Warner2, E. Johnston2, L. Flanders3, P. Hendy4, N. Ding4, R. Harris5, A.S. Fadra6, C. Basquill1, C.A. Lamb7, F. Cameron8, 9, A. Singh10, J. Mason11, C. Christodoulou12, C. Stansfield13, E. Nowell14, U. Basavaraju15, K. Lithgo16, D. Maggs17, A. Mohsini17, F.R. Cummings18, M. Jonston16, D.C. Wilson9, J. Thomson15, S. Lal13, M. Parkes12, R. Russell8, I. Gooding11, T. Ahmad10, D.R. Gaya19, J. Mansfield20, S. Mann21, J. Lindsay6, J. Gordon5, A. Hart4, S. McCartney3, P. Irving2, J. Satsangi1, C.W. Lees1
1Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, 2Guy's & St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom, 3University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom, 4St Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom, 5Royal Hampshire County Hospital, Hampshire Hospitals NHS Foundation Trust, Department of Gastroenterology, Winchester, United Kingdom, 6The Royal London Hospital, Barts Health NHS Trust Department of Gastroenterology, London, United Kingdom, 7Newcastle University, Institute of Cellular Medicine, Newcastle Upon Tyne, United Kingdom, 8Royal Hospital for Sick Children, Paediatric Gastroenterology, Glasgow, United Kingdom, 9University of Edinburgh, Paediatric Gastroenterology and Nutrition, Child Life and Health, Edinburgh, United Kingdom, 10Royal Devon and Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom, 11Colchester Hospital University NHS Foundation Trust, Gastroenterology, Colchester, United Kingdom, 12Addenbrooke's Hospital, Gastroenterology, Cambridge, United Kingdom, 13Salford Royal NHS Foundation Trust, Gastroenterology, Salford, United Kingdom, 14Hairmyres Hospital, Gastroenterology, East Kilbride, United Kingdom, 15Aberdeen Royal Infirmary, Gastroenterology, Aberdeen, United Kingdom, 16Luton & Dunstable University Hospital foundation trust NHS, Gastroenterology, Luton, United Kingdom, 17North Bristol NHS Trust, Gastroenterology, Bristol, United Kingdom, 18University Hospital Southampton, Gastroenterology, Southampton, United Kingdom, 19Glasgow Royal Infirmary, Gastroenterology, Glasgow, United Kingdom, 20Royal Victoria Infirmary, Gastroenterology, Newcastle upon Tyne, United Kingdom, 21Barnet & Chase Farm Hospitals, Royal Free London NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom
Lémann Index assessment over time in Crohn's disease patients treated with anti TNFs: a pilot observational cohort study
G. Fiorino1, M. Allocca1, C. Bonifacio2, P. Naccarato1, F. Mrakic Sposta2, A. Spinelli3, L. Balzarini1, S. Danese1, 1Humanitas Research Hospital, IBD Center, Rozzano, Milan, Italy, 2Humanitas Research Hospital, Radiology, Rozzano, Milan, Italy, 3Humanitas Research Hospital, IBD Surgery Unit, Milano, Italy
PYRAMID registry: an observational study of adalimumab in Crohn's disease: Results at year 6
G. D'Haens*1, W. Reinisch2, 3, J. Satsangi4, E.V. Loftus, Jr5, R. Panaccione6, K.L. Wallace7, A. Deshmukh8, S. Eichner9, A.M. Robinson7, R.B. Thakkar7
1Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, 2McMaster University, Gastroenterology, Hamilton, Canada, 3Medical University of Vienna, Dept. for Gastroenterology and Hepatology, Vienna, Austria, 4Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, 5Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, MN, United States, 6University of Calgary, Department of Medicine, Calgary, Canada, 7AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, United States, 8AbbVie Inc., Statistics, North Chicago, United States, 9AbbVie Inc., Global Medical Affairs, North Chicago, United States
Long-term outcome of paediatric-onset ulcerative colitis: early years are shaping the future
C. Gower-Rousseau1,2, H. Sarter3, D. Turck4, M. Fumery5, E. Laberenne6, F. Vasseur1, L. Peyrin-Biroulet7, J.-F. Colombel8, G. Savoye9, A. Peneau10, C. Spyckerelle11, 1University and Hospital, Epidemiology, Lille, France, 2Health, Epidemiology, Lille, France, 3University and Hospital, Epimad Registry Biostatistics EA 2694, Lille, France, 4University and Hospital, Paediatric, Lille, France, 5University and Hospital, Gastroenterology, Amiens, France, 6Hospital, Gastroenterology, Seclin, France, 7University and Hospital, Gastroenterology, Nancy, France, 8Hemsley Inflammatory Bowel Disease Center, Icahn Medical School of Medicine at Mount Sinai, New-York, United States, 9University and Hospital, Gastroenterology, Rouen, France, 10University and Hospital, Gastroenterology, Lille, France, 11Catholic University & Hospital, Paediatric, Lille, France
Initial Adequate Trough Concentrations during Induction Therapy Correlate with Sustained TNF Suppression and Predict Remission with Adalimumab in Anti-TNF Naïve Crohn's Disease Patients
N. Vande Casteele*1, 2, D. Mould3, S. Tops1, K. Vandenbroeck4, V. Ballet4, M. Ferrante4, G. Van Assche4, A. Gils1, S. Vermeire4, F. Baert5
1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Therapeutic and Diagnostic Antibodies, Leuven, Belgium, 2University of California San Diego, Division of Gastroenterology, IBD center, La Jolla, CA, United States, 3Projections Research Inc, Projections Research Inc, Phoenixville, United States, 4University Hospitals Leuven, Gastroenterology - Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 5H.-Hartziekenhuis - AZ Delta, Gastroenterology, Roeselare, Belgium
Adolescent and young adults are more likely to require total colectomy in ulcerative colitis: UK population based cohort study
V. Chhaya1, R. Pollok1, E. Cecil2, A. Majeed2, S. Saxena2, 1St George's University of London, Gastroenterology, London, United Kingdom, 2Imperial College London, Primary care and Public Health, London, United Kingdom
Faecal calprotectin measurement and infliximab trough levels predict therapeutic evolution CD patients in clinical remission
X. Roblin*1, G. Duru2, L. Clavel1, M. Rinaudo3, M. Cuilleron4, C. Jarlot1, J.M. Phelip1, L. Peyrin Biroulet5, S. Paul3
1University Hospital, Gastroenterology, Saint Etienne, France, 2University Hospital, Statistic, Lyon, France, 3University of Saint Etienne, Immunology, Saint Etienne, France, 4University hospital, Radiology, Saint Etienne, France, 5CHU de Nancy, Department of Gastroenterology, Vandoeuvre-les-Nancy, France
Development of MRE based multi item measures of inflammation and intestinal damage in paediatric Crohn's disease: the ImageKids study
P. Church1, M.-L. Greer2, A. Griffiths1, M.M. Amitai3, T. Walters1, R. Cytter-Kuint2, G. Focht4, D. Turner5, 1University of Toronto, The Hospital for Sick Children, Division of Gastroenterology, Hepatology and Nutrition, Toronto, Canada, 2The Hospital for Sick Children/University of Toronto, Diagnostic Imaging, Toronto, Canada, 3Sheba Medical Center, Department of Diagnostic Imaging, Tel Hashomer, Israel, 4Shaare Zedek Medical Centre, Pediatric Gastroenterology and Nutrition, Jerusalem, Israel, 5Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Pediatric Gastroenterology, Jerusalem, Israel
Early therapeutic drug monitoring for prediction of short-term mucosal healing in patients with ulcerative colitis treated with infliximab
K. Papamichail*1, 2, N. Vande Casteele3, T. Billiet1, A. Gils3, S. Tops3, K. Claes1, G.A. Van Assche1, P.J. Rutgeerts1, S. Vermeire1, M. Ferrante1
1KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID), Leuven, Belgium, 2Evaggelismos Hospital, Gastroenterology Clinic, Athens, Greece, 3KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Therapeutic and Diagnostic Antibodies, Leuven, Belgium
Anti-TNF-α therapies are safe during pregnancy in patients with inflammatory bowel disease: a meta-analysis
N. Narula1, R. Al-Dabbagh1, A. Dhillon2, J. Marshall1, 1McMaster University, Gastroenterology, Hamilton, Canada, 2Northern Ontario School of Medicine, Internal Medicine, Sudbury, Canada
Relationship between vedolizumab pharmacokinetics and endoscopic outcomes in patients with Ulcerative Colitis
M. Rosario*1, B. Abhyankar2, S. Sankoh3, N. Dirks4, K. Lasch5, W. Sandborn6
1Takeda Pharmaceuticals International Co., Clinical Pharmacology, Cambridge, United States, 2Takeda Global Research & Development Centre (Europe) Ltd., GI Clinical Science, London, United Kingdom, 3Takeda Pharmaceuticals International Co., Global Statistics, Cambridge, United States, 4Metrum Research Group, LLC, Biotechnology, Tariffville, United States, 5Takeda Pharmaceuticals International, Inc., GI Medical Affairs, US Region, Deerfield, United States, 6University of California San Diego, Division of Gastroenterology, La Jolla, United States
Intra-uterine ExposuRe to Anti-TNF-alpha therapy (ERA study): Infliximab and adalimumab cord blood levels correlate with maternal levels at birth
M. Julsgaard1,5, L.A. Christensen1, J. Fallingborg2, R. Gearry3, G. Radford-Smith4, A. Walsh5, J. Kjeldsen6, M.P. Sparrow7, J.M. Andrews8, S.J. Connor9, I. Lawrence10, P.R. Gibson7, O. Rosella7, A. Grosen1, S.J. Bell11, 1Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark, 2Aalborg Hospital, Department of Gastroenterology, Aalborg, Denmark, 3University of Otago, Christchurch hospital, Dept. of Medicine (Gastroenterology), Christchurch, New Zealand, 4Royal Brisbane and Women's Hospital, Gastroenterology, Brisbane, Queensland, Australia, 5St Vincent's Hospital, Dept. of Gastroenterology, Sydney, Australia, 6Odense University Hospital, Dept. of Gastroenterology and Hepatology, Odense, Denmark, 7Alfred Hospital and Monash University, Dept. of Gastroenterology, Melbourne, Australia, 8Royal Adelaide Hospital, University of Adelaide, IBD Service, Dept of Gastroenterology & Hepatology & School of Medicine, Adelaide, Australia, 9Liverpool Hospital & University of NSW, Dept. of Gastroenterology, Sydney, Australia, 10Fremantle Hospital, Centre for Inflammatory Bowel Disease, Fremantle, Australia, 11St Vincent's Hospital & University of Melbourne, Gastroenterology, Melbourne, Australia
Etrolizumab population pharmacokinetics (Pop PK) and covariate analysis in patients with moderately to severely active ulcerative colitis (UC)
X.T. Wei*, D. Luca, Y. Wang, S. O'Byrne, R. Erickson, J.D. Davis, M.T. Tang
Genentech, Clinical Pharmacology, South San Francisco, United States
Large variation in infliximab trough levels is associated with disease activity in paediatric inflammatory bowel disease
D. Hoekman1, H. Brandse2, T. de Meij3, T. Hummel4, M. Löwenberg2, M. Benninga1, G. D'Haens2, A. Kindermann1, 1Academic Medical Center/Emma Children's Hospital, Department of Paediatric Gastroenterology and Nutrition, Amsterdam, Netherlands, 2Academic Medical Center, Department of Gastroenterology, Amsterdam, Netherlands, 3VU University Medical Center, Pediatric Gastoenterology, Amsterdam, Netherlands, 4Medisch Spectrum Twente, Pediatric Gastoenterology, Enschede, Netherlands
Clinical response and remission with vedolizumab across a range of baseline fecal calprotectin levels in ulcerative colitis: Results from GEMINI 1
W. Reinisch*1, J.D. Lewis2, T. Dassopoulos3, P. Ginsburg4, B.E. Sands5, B. Feagan6, S. Danese7, A.G. Roseth8, M. Rosario9, H. Yang10, A. Parikh11, B. Bressler12, T. Wyant13
1McMaster University, Department of Medicine, Hamilton, Canada, 2University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States, 3Washington University School of Medicine, Gastroenterology Division, St. Louis, United States, 4Gastroenterology Center of Connecticut, Physician, Hamden, United States, 5Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States, 6University of Western Ontario, Robarts Research Institute, London , Canada, 7Istituto Clinico Humanitas, Division of Gastroenterology, Milano, Italy, 8Lovisenberg Diakonale Hospital, Medical Department, Oslo, Norway, 9Takeda Pharmaceuticals International Company, Pharmacology, Cambridge, United States, 10Takeda Pharmaceuticals International Company, Statistics, Cambridge, United States, 11Takeda Pharmaceuticals International, Inc., General Medicine, Deerfield, United States, 12University of British Columbia, Division of Gastroenterology, Vancouver, Canada, 13Takeda Pharmaceuticals International Company, Translational Medicine, Cambridge, United States
The role of thiopurines in reducing the need for first intestinal resection in Crohn's disease: A systematic review and meta-analysis
S. Chatu1, V. Subramanian2, S. Saxena3, R. Pollok1, 1St Georges University Hospital, Gastroenterology, London, United Kingdom, 2St Jame's University Hospital, Center for Digestive Diseases, Leeds, United Kingdom, 3Imperial College London, Primary care and Public Health, London, United Kingdom
Faecal calprotectin as a tool for relapse prediction in clinical routine in Crohn's Disease patients − preliminary Results from the prospective, population-based FIRE study
S. Nikolaus*1, D. Lang2, B.M. Wittig2, M. Schwarz2, S. Schreiber1
1University Hospital Schleswig-Holstein, Internal Medicine I, Kiel, Germany, 2AbbVie Deutschland GmbH & Co. KG, Medical Department, Wiesbaden, Germany